Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of BAY2327949 in Renal Impairment
NCT04004195Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enuvaptan in chronic kidney disease (CKD) (4 arms), sponsored by Bayer. Primary endpoints: Cmax of BAY2327949, AUC of BAY2327949 and 2 more. Started Jul 2019; status: completed.
02
Drugs
enuvaptan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04004195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004195.